Lista de obras - F Gelsomino - Dominio Público Uruguay

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

artículo científico publicado en 2017

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

article

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

artículo científico publicado en 2011

Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding

artículo científico publicado en 2018

Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients

article

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)

scientific article published on 20 July 2020

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

artículo científico publicado en 2018

Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

artículo científico publicado en 2015

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

artículo científico publicado en 2011

Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC)

artículo científico publicado en 2018

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

artículo científico publicado en 2013

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

artículo científico publicado en 2014

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?

artículo científico

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations

artículo científico publicado en 2010

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2010

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story ⬇️

artículo científico publicado el 12 de agosto de 2013

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

scientific article published on 01 October 2020

FGFR as potential target in the treatment of squamous non small cell lung cancer

artículo científico

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

artículo científico publicado en 2016

Immune-mediated cholangitis: is it always nivolumab's fault?

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

artículo científico publicado en 2014

MET and ALK as targets for the treatment of NSCLC.

artículo científico publicado en 2014

MET and Small-Cell Lung Cancer

artículo científico publicado en 2014

Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review.

artículo científico publicado en 2017

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event

artículo científico publicado en 2020

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

artículo científico

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

scientific article published on 29 April 2020

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.

artículo científico publicado en 2016

Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer

artículo científico publicado en 2016

Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

artículo científico publicado en 2017

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

artículo científico publicado en 2019

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

artículo científico publicado en 2011

Targeting the MET gene for the treatment of non-small-cell lung cancer

artículo científico publicado en 2013

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

artículo científico publicado en 2018

The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer

artículo científico publicado en 2016

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer

artículo científico publicado en 2018

Lista de obras de F Gelsomino

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding

Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC)

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story ⬇️

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

FGFR as potential target in the treatment of squamous non small cell lung cancer

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

Immune-mediated cholangitis: is it always nivolumab's fault?

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

MET and ALK as targets for the treatment of NSCLC.

MET and Small-Cell Lung Cancer

Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review.

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.

Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer

Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

Targeting the MET gene for the treatment of non-small-cell lung cancer

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer